A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer	Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder	Active, not recruiting	Phase 1	2026-07-06		NCT04898634

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Janssen Research & Development, LLC	188

17 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Antoni van Leeuwenhoek	Amsterdam	Netherlands	15
APHM Hopital Timone	Marseille	France	2
Centre Leon Berard	Lyon	France	70
Chongqing University Cancer Hospital	Chongqing	China	29
Columbia University Medical Center Herbert Irving Pavilion	New York	United States	2
Erasmus MC	Rotterdam	Netherlands	44
First Affiliated Hospital Of Wenzhou Medical College	Wenzhou	China	1
Hosp Univ Fund Jimenez Diaz	Madrid	Spain	33
Hosp Univ Hm Sanchinarro	Madrid	Spain	17
Hosp Virgen de La Victoria	Málaga	Spain	19
Institut Gustave Roussy	Villejuif	France	54
Memorial Sloan Kettering Cancer Center	New York	United States	1000
National Cancer Center Hospital East	Kashiwa	Japan	14
Peking University Third Hospital	Beijing	China	71
Sun Yat Sen University Cancer Center	Guangzhou	China	3
University of Washington	Seattle	United States	2
Yokohama City University Medical Center	Yokohama	Japan	19